Browse Category

Forecast News 27 June 2025 - 19 August 2025

Category 4 Hurricane Erin Churns Off East Coast – Live Tracking, Forecast Path & Expert Warnings

Category 4 Hurricane Erin Churns Off East Coast – Live Tracking, Forecast Path & Expert Warnings

Erin is a Category 4 hurricane with sustained winds near 130 mph as of Aug. 18, 2025. The NHC placed Erin’s center near 24.1°N, 71.5°W, about 695 miles southwest of Bermuda. Hurricane-force winds extend about 80 miles from the center, and tropical-storm-force winds reach up to 230 miles. Forecast models indicate Erin will recur north between Bermuda and the U.S. East Coast, stay offshore, turn north on Tuesday, and accelerate northeast into the open Atlantic. Erin reached Category 5 on Aug. 16, 2025, with peak winds near 160 mph, in just over 27 hours from tropical-storm strength, making it the
19 August 2025
Top Biotechnology and Health Tech Trends in 2025: Mid-Year Update and Forecast (Updated: June 27th, 2025)

Top Biotechnology and Health Tech Trends in 2025: Mid-Year Update and Forecast (Updated: June 27th, 2025)

Late 2024, the first FDA-approved CRISPR-based therapy exagamglogene autotemcel (Casgevy) reached patients, with Vertex reporting $2 million in revenue from this sickle-cell gene-editing therapy in Q3 2024. Prime Medicine’s PM359 autologous CRISPR prime-edited cell therapy for chronic granulomatous disease began a Phase I/II study in 2024, with initial first-in-human data expected in late 2025. Wave Life Sciences’ RNA base-editing drug WVE-006 showed proof-of-mechanism in humans in 2024, and multi-dose trial data are anticipated in 2025. In April 2025, the FDA approved Abeona Therapeutics’ Zevaskyn, the first cell-based gene therapy for the rare skin disorder RDEB, with launch planned in Q3
Go toTop